Clinical trials
Salivary Gland Tumor clinical trials
Below are recruiting salivary gland tumor clinical trials, each written for real people, not researchers. We’re tracking 25 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05000892RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for salivary cancer
This trial studies giving an immunotherapy drug (sintilimab) plus two chemotherapy medicines before surgery to shrink salivary gland cancer. The goal is to improve how well the cancer responds and is controlled, while still aiming for a cure through surgery.
Guangzhou, GuangdongAges 18–80 - NCT04452162Recruiting
MRI study for salivary gland tumors
This trial uses special MRI scans to learn how salivary gland tumors work in the body. It may help improve diagnosis and how tumors are evaluated without needing treatment yet.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05408845RecruitingPhase 2
Study drug vs standard care for HER2 salivary gland cancer
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Birmingham, AlabamaAges 18 years+ - NCT06047236Recruiting
Immune markers in salivary gland cancer
This study looks at immune cells and substances in blood, saliva, and stool from people with salivary gland cancer. The goal is to find markers that could help predict how the disease behaves.
Erlangen, BavariaAges 18 years+ - NCT06805617RecruitingPhase 2
Ivonescimab for advanced salivary gland cancer
This trial tests a new drug called Ivonescimab for people with advanced salivary gland cancer that has spread or cannot be removed surgically. The goal is to see if the drug can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT07072143Recruiting
Study on children with rare tumors
This study is looking at children and teens with very rare tumors to learn more about these conditions and improve future care. It aims to gather information from patients treated at participating centers.
Padova, ItalyAges birth–18 years - NCT01365169Recruiting
How activity level and daily function relate to cancer survival
This study looks at how physical activity (movement during the day) and a clinician-rated “day-to-day function” score relate to overall survival in people with certain cancers. It may help doctors understand who benefits most from activity-focused care and better monitoring.
Houston, TexasAges 18 years+ - NCT04620187RecruitingPhase 2
Study medicine T-DM1 after surgery for HER2-positive salivary cancer
This Phase 2 trial studies T-DM1 given after surgery for salivary gland cancer that is HER2-positive. The goal is to reduce the risk of the cancer coming back by targeting HER2-positive tumor cells.
Atlanta, GeorgiaAges 18 years+ - NCT07755397RecruitingPhase 1
Study of JBI-778 for lung, brain, and salivary gland tumors
This trial tests a new oral medication, JBI-778, in patients with certain types of lung cancer, brain tumors, or salivary gland cancer. The drug is designed to target specific genetic changes in these tumors, and the study aims to assess its safety and effectiveness.
Surat, GujaratAges 18 years+ - NCT04969835RecruitingPhase 1
Safety and early response study of AVA6000 for solid tumors
This Phase 1 study tests AVA6000 in people with certain solid tumor cancers, mainly to check safety and how the body processes the drug. It also looks for early signs of tumor response to see if it might help further in later studies.
New York, New YorkAges 18 years+ - NCT05727410RecruitingPhase 2
Nivolumab and chemotherapy before surgery and radiation for salivary cancer
This Phase 2 study tests giving nivolumab plus docetaxel and cisplatin before surgery and radiation for certain resectable, high-grade salivary gland cancers. It aims to shrink or control the cancer early to improve outcomes after treatment.
SeoulAges 19 years+ - NCT05553782RecruitingEarly Phase 1
IMD device study for certain head and neck cancers
This early-phase study tests a new small device (placed through the skin) plus standard surgery to study head and neck cancers. It may help researchers understand how the device works and gather safety information for people who need definitive surgery for a measurable tumor.
Boston, MassachusettsAges 18 years+ - NCT05884320RecruitingPhase 2
Sacituzumab govitecan for advanced salivary gland cancers
This Phase 2 trial tests sacituzumab govitecan, an anti-cancer medicine, in people with recurrent or metastatic (coming back or spread) secretory gland cancers or related salivary gland cancers. It aims to see how well the treatment can shrink tumors and control disease when surgery or radiation is not a cure.
Houston, TexasAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT06145308RecruitingPhase 2
Precision treatment for salivary gland cancer
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
Beijing, Beijing MunicipalityAges 18–100 - NCT07464366RecruitingPhase 2
MRG003 with or without putrelimab for salivary gland cancer
This trial tests a new drug combination (MRG003 with or without putrelimab) for people with advanced salivary gland cancer that has EGFR protein. It aims to see if the treatment is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06356272Recruiting
Oropharynx cancer biomarker study
This study looks at certain markers (called p16 and HPV) in tumor samples to better understand oropharynx cancer. It may help doctors learn more about the disease and guide future treatments.
Rochester, MinnesotaAges 18 years+ - NCT02012699Recruiting
Cancer registry for people with or at risk of cancer
This trial collects health information and samples (a “cancer repository”) to help researchers study cancer and cancer risk. You may be able to join if you’ve had cancer before or if you’re at higher risk or have concerning findings.
Greenwood Village, ColoradoAges 19–110 - NCT03740256RecruitingPhase 1
HER2-targeted oncolytic virus plus custom immune cells for solid cancers
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Houston, TexasAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT05483374Recruiting
Head and neck cancer registry for adult patients
This study builds a European database (registry) of adults with certain head and neck cancers to better understand how these cancers are diagnosed and treated over time. It may help future care by collecting real-world information, rather than testing a new medicine.
Brno, BrnoAges 18 years+ - NCT06393140Recruiting
Study of how radiation affects the immune system in esophageal cancer
This study looks at how radiation therapy affects your immune system. It helps researchers understand your body's response after treatment, which may lead to better care for esophageal cancer.
ShanghaiAges 18 years+ - NCT06686979Recruiting
Drug sensitivity test for advanced salivary gland cancer
This trial tests whether a laboratory-grown mini-tumor (organoid) from your biopsy can predict which drugs will work best for your recurrent or metastatic salivary gland cancer. You would need to provide a tumor sample and have adequate organ function.
Shanghai, Shanghai MunicipalityAges 18–80
Hear when a new Salivary Gland Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for salivary gland tumor?
- Yes. Clin2 currently lists 25 recruiting salivary gland tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a salivary gland tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a salivary gland tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.